Our research pipeline explores innovative biologics designed to address critical challenges in oncology, metabolic disorders, and beyond. These advanced therapeutic candidates have been validated in multiple preclinical in vivo and in vitro models, showing strong potential across a variety of medical applications.

The initial focus is on well-characterized molecular targets that regulate angiogenesis, tumor growth, and metabolic pathways. By leveraging cutting-edge biologic platforms, each candidate is optimized for long-lasting efficacy, high selectivity, and improved patient outcomes.

TSP-1 Mimetic Therapeutic Targeting Tumor Angiogenesis

This candidate is a long-acting Thrombospondin-1 (TSP-1) mimetic biologic, designed to inhibit abnormal blood vessel formation in tumors. Preclinical studies across multiple xenograft models have demonstrated significant anti-angiogenic activity and tumor suppression.

• Mechanism: Negative regulation of angiogenesis through TSP-1 pathways
• Potential Impact: Offers an alternative to VEGF-targeted therapies, with promising results in combination treatments and VEGF-resistant tumors
• Clinical Pathway: Supported by strong preclinical data and currently advancing toward clinical evaluation

Angiopoietin-2 Antagonist Selective Inhibition of Ang2

This therapeutic candidate specifically binds and neutralizes Angiopoietin-2 (Ang2), a critical mediator of angiogenesis that is often linked to poor prognosis in solid and hematologic malignancies.

• Mechanism: High selectivity for Ang2 over Ang1, blocking tumor vascularization
• Preclinical Results: Demonstrated strong in vitro binding, in vivo efficacy, and durable pharmacokinetics
• Therapeutic Benefit: Substantially reduces tumor growth and microvascular density in models
• Combination Therapy: Enhanced effectiveness when paired with traditional chemotherapeutics or other targeted agents

GLP-1 Mimetic Long-Acting Metabolic Regulator

Our research also extends into metabolic disease therapy, with a long-acting GLP-1 mimetic biologic showing superior pharmacological performance in preclinical studies.

• Pharmacokinetics: Extended half-life (up to 66 hours in animal models)
• Potency and Delivery: High bioavailability and strong subcutaneous absorption
• Development Stage: Toxicology studies are in progress, with plans to advance toward clinical trials
• Potential Impact: Offers a novel therapeutic strategy for metabolic disorders and diabetes management with improved dosing convenience

Summary

Through this pipeline, we aim to redefine biologic therapy by creating innovative solutions in oncology and metabolic health. Each candidate leverages an advanced biologic scaffold for consistent development, manufacturing efficiency, and reduced clinical risk.

Our long-term goal is to bring next-generation therapeutics that not only improve patient outcomes but also expand treatment options where traditional therapies have shown limitations.